Compare RBC & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBC | DVA |
|---|---|---|
| Founded | 1919 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7B | 14.9B |
| IPO Year | 2005 | 2003 |
| Metric | RBC | DVA |
|---|---|---|
| Price | $483.88 | $191.63 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 4 |
| Target Price | ★ $510.00 | $156.75 |
| AVG Volume (30 Days) | 252.9K | ★ 545.4K |
| Earning Date | 05-15-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.05 | N/A |
| EPS | 3.20 | ★ 6.86 |
| Revenue | $1,870,900,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $15.20 | $3.85 |
| Revenue Next Year | $12.36 | $3.07 |
| P/E Ratio | $151.16 | ★ $27.83 |
| Revenue Growth | ★ 14.34 | 6.46 |
| 52 Week Low | $364.50 | $101.00 |
| 52 Week High | $667.69 | $247.49 |
| Indicator | RBC | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 36.53 | 54.97 |
| Support Level | $447.35 | $189.09 |
| Resistance Level | $587.23 | $202.63 |
| Average True Range (ATR) | 12.42 | 4.90 |
| MACD | 1.29 | 2.81 |
| Stochastic Oscillator | 26.41 | 97.25 |
RBC Bearings is an international manufacturer and marketer of engineered precision bearings, components, and essential systems for the industrial, defense, and aerospace industries. The offering includes plain bearings, roller bearings, ball bearings, and engineered products. The company has two reportable segments: industrial, which generates the most revenue, and aerospace and defense. The A&D segment represents the end markets for the company's engineered bearings and precision components used in commercial aerospace, defense aerospace, and sea and ground defense applications; and the industrial segment represents the end markets for its products used in various industrial applications. Geographically, the company generates a majority of its revenue from the United States.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.